tickrz reports
tickrz rank
D
Bristol-Myers Squibb Co (BMY)
Healthcare | Drugs
62.93  0.37%
FACTOR RANKINGSFACTOR SCREENER 
tickrz RankD / 398Warren Buffett RankD / 377
Pure Value RankD / 362Dividend RankB / 104
Moat RankD / 363Financial Strength RankB / 124
Growth RankD / 385Momentum RankC / 334
BMY vs DRUGS SECTOR & S&P 500
VALUATION
BMYSECTORS&P 500
P/E RATIO22.435.719.28
EV/EBITDA RATIO15.6325.111.77
P/S RATIO5.087.12.03
P/B RATIO6.998.73.09
QUALITY
RETURN ON EQUITY30.51%16.98%13.82%
RETURN ON CAPITAL24.45%26.23%10.04%
NET MARGIN22.94%14.46%9.76%
DIVIDEND ANALYSIS
DIVIDEND YIELD
2.48%
PAYOUT RATIO56.33%
3 YR DIVIDEND GROWTH2.76%
FINANCIAL STRENGTH
PIOTROSKI F SCORE
6 OUT OF 9
DEBT-TO-EQUITY55%
INTEREST COVERAGE29.26x
CURRENT RATIO1.59
GROWTH
5 YR EPS GROWTH4.17%
5 YR SPS GROWTH-1.77%
5 YR BPS GROWTH0.53%
About tickrz
Key Concepts
Great Investors
tickrz Report
tickrz rank D / 398
Bristol-Myers Squibb Co receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
value
pure value ranking D / 362Warren Buffett ranking D / 377
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Bristol-Myers Squibb Co's valuation score is comprised of a P/E ratio of 22.4x, a P/B ratio of 7x, a P/S ratio of 5.1x, and an EV/EBITDA ratio of 15.6x. Bristol-Myers Squibb Co ranks 362 out of the S&P 500 constituents on valuation--a relatively weak score.Bristol-Myers Squibb Co ranks 377 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a weak score, meaning it ranks poorly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Bristol-Myers Squibb Co is probably not for you.

quality
moat D / 363financial strength B / 124
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is weak. Its position within the Healthcare sector appears to be weak. Either the dynamics of its sector place it in a difficult position or management's executition is to blame for its disappointing performance.Bristol-Myers Squibb Co has a Piotroski F Score of 6 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 29.26x, a debt/equity ratio of 55% and a Moat Rank of 363 translate to an average Financial Strength score.


momentum C / 334
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 3.39% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 334. Based on its 12 month stock performance, Bristol-Myers Squibb Co will not appeal to momentum investors.

yield B / 104
value + yield
Shares currently yield 2.48%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, Bristol-Myers Squibb Co ranks 104 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

growth D / 385
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the bottom third of S&P500 companies. Its 4.2% 5 year annualized EPS growth, -1.8% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 0.5% speak to its relatively poor ranking.

Bristol-Myers Squibb Co (BMY)
Healthcare | Drugs
62.93  0.37%


tickrz rank
D
VALUATION RATIOS
P/E Ratio22.4x
P/B Ratio6.99x
P/S Ratio5.08x
EV/EBITDA Ratio15.63x
DIVIDEND ANALYSIS
DIVIDEND YIELD
2.48%
PAYOUT RATIO56.33%
3 YR DIVIDEND GROWTH2.76%
FINANCIAL STRENGTH
PIOTROSKI F SCORE
6 OUT OF 9
DEBT-TO-EQUITY55%
INTEREST COVERAGE29.26x
CURRENT RATIO1.59
MOAT
ROE30.51%
ROIC24.45%
Net Margin22.94%
GROWTH
5 YR EPS GROWTH4.17%
5 YR SPS GROWTH-1.77%
5 YR BPS GROWTH0.53%

TICKRZ RANK
Bristol-Myers Squibb Co receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Bristol-Myers Squibb Co's valuation score is comprised of a P/E ratio of 22.4x, a P/B ratio of 7x, a P/S ratio of 5.1x, and an EV/EBITDA ratio of 15.6x. Bristol-Myers Squibb Co ranks 362 out of the S&P 500 constituents on valuation--a relatively weak score.

WARREN BUFFETT RANKING
Bristol-Myers Squibb Co ranks 377 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a weak score, meaning it ranks poorly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Bristol-Myers Squibb Co is probably not for you.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is weak. Its position within the Healthcare sector appears to be weak. Either the dynamics of its sector place it in a difficult position or management's executition is to blame for its disappointing performance.

FINANCIAL STRENGTH
Bristol-Myers Squibb Co has a Piotroski F Score of 6 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 29.26x, a debt/equity ratio of 55% and a Moat Rank of 363 translate to an average Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 3.39% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 334. Based on its 12 month stock performance, Bristol-Myers Squibb Co will not appeal to momentum investors.

VALUE + YIELD
Shares currently yield 2.48%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, Bristol-Myers Squibb Co ranks 104 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the bottom third of S&P500 companies. Its 4.2% 5 year annualized EPS growth, -1.8% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 0.5% speak to its relatively poor ranking.